Renal Tubular Acidosis Management in Chronic Kidney Disease

Diagnostic Confirmation

A blood‑gas analysis showing pH < 7.35 with serum bicarbonate < 22 mmol/L confirms the presence of metabolic acidosis in CKD patients and distinguishes it from respiratory compensation. 1

The American Society of Nephrology recommends initiating oral alkali therapy (potassium citrate or sodium bicarbonate) to keep serum bicarbonate ≥ 22 mmol/L, which helps prevent bone disease, nephrocalcinosis, reduces stone recurrence, and may slow CKD progression. 2
If potassium citrate is not tolerated, sodium bicarbonate 0.5–1.0 mEq/kg/day (approximately 25–50 mEq/day) divided into 2–3 doses is an acceptable alternative, although it does not provide the stone‑protective effect of citrate. 1
Maintaining serum bicarbonate ≥ 22 mmol/L is specifically advised to avoid bone demineralization, growth retardation in children, and progressive nephrocalcinosis. [2][1]

Serum bicarbonate should be measured monthly after therapy initiation, then every 3 months once stable; concurrent monitoring of potassium, calcium, and phosphorus is also required. [2][1]
During dose titration, check serum bicarbonate, potassium, sodium, chloride, calcium, and phosphorus every 2–4 weeks; after stabilization, repeat these labs every 3 months. [2][1]
Blood pressure must be assessed at each visit because sodium‑containing alkali can exacerbate hypertension and volume overload in CKD patients. 1
Citrate‑containing alkali should be avoided in patients receiving aluminum‑based phosphate binders, as citrate increases aluminum absorption and worsens bone disease. 1

Serum bicarbonate should be kept ≥ 22 mmol/L with monitoring at least every 3 months to prevent protein catabolism, bone disease, and further CKD progression. [2][1]3
When bicarbonate falls below 18 mmol/L, start sodium bicarbonate therapy at 0.5–1.0 mEq/kg/day. 1
Increasing intake of fruits and vegetables (which provide potassium citrate salts) offers additional benefits, including lower systolic blood pressure and reduced net acid production beyond what bicarbonate alone achieves. 1

Patients with progressive CKD and persistent metabolic acidosis should be prepared for renal replacement therapy when the 1‑year risk of kidney failure exceeds 10–20 %; dialysis provides definitive correction of acid‑base disturbances. [4][3]